These results represent a pivotal step forward in understanding the potential of blood RKIP and pRKIP as biomarkers for the early diagnosis of lung cancer, paving the way for more effective, non-invasive diagnostic tools that could transform patient outcomes and alter the course of this devastating disease. This evidence concerns the gene PEBP1 and lung cancer.